The protective effect of chondroitin sulfate on induced arthritis in rats.

The protective effect of chondroitin sulfate on induced arthritis in rats

Antiproliferative activity and apoptosis induced by 6-bromo-2-(morpholin-1-yl)-4-anilinoquinazoline on cells of leukemia lines

Quinazolines are known to be multitarget agents with broad spectrum of biological activity. Aim: To investigate anticancer activity of newly prepared 6-bromo-2-(morpholin-1-yl)-4-anilinoquinazoline (BMAQ) towards L1210, HL-60 and U-937 leukemia cells. Materials and Methods: Growth inhibition of BMAQ-treated cells was determined by cell counting using trypan blue staining technique. Apoptosis and cell cycle profile changes were analysed using internucleosomal DNA fragmentation assay, fluorescence microscopy and flow cytometry. Activity of caspase-3 was determined using colorimetric method. Results: Cell proliferation assay showed that BMAQ caused significant decrease of cell number in a dose-dependent manner. BMAQ induced cell death by apoptosis, based on results from DNA fragmentation, fluorescence microscopy and caspase-3 assays. Conclusion: Presented results clearly demonstrate that BMAQ is a promising anticancer agent with significant antiproliferative and apoptotic activities towards leukemia cells in vitro.Квиназолины известны как химиопрепараты широкого спектра действия. Цель: на моделях лейкозных клеток линий L1210, HL-60 и U-937 изучить противоопухолевую активность нового препарата 6-бромо-2-(морфолин-1-ил)-4-аналиноиназолина (BMAQ). Методы: ингибирование роста клеток под действием BMAQ изучали путем подсчета количества клеток, окрашенных трипановым синим. Апоптоз и изменения профиля клеточного цикла исследовали с помощью флуоресцентной микроскопии, электрофореза ДНК и проточной цитометрии. Активность каспазы-3 определяли колориметрическим методом. Результаты: показано, что BMAQ вызывает значительное дозозависимое уменьшение количества лейкозных клеток. При этом клетки, обработанные BMAQ, погибают путем апоптоза, что дается образованием апоптотических телец, межнуклеосомной фрагментацией ДНК и активацией каспазы-3. Выводы: представленные результаты свидетельствуют о том, что BMAQ обладает антипролиферативной и проапоптотической активностью в отношении лейкозных клеток in vitro

Fungal vaccines and immunotherapeutics: current concepts and future challenges

Purpose of review The remarkable advances in modern medicine have paradoxically resulted in a rapidly expanding population of immunocompromised patients displaying extreme susceptibility to life-threatening fungal infections. There are currently no licensed vaccines, and the prophylaxis and therapy of fungal infections in at-risk individuals remains challenging, contributing to undesirable mortality and morbidity rates. The design of successful antifungal preventive approaches has been hampered by an insufficient understanding of the dynamics of the host-fungus interaction and the mechanisms that underlie heterogenous immune responses to vaccines and immunotherapy. Recent findings Recent advances in proteomics and glycomics have contributed to the identification of candidate antigens for use in subunit vaccines, novel adjuvants, and delivery systems to boost the efficacy of protective vaccination responses that are becoming available, and several targets are being exploited in immunotherapeutic approaches. Summary We review some of the emerging concepts as well as the inherent challenges to the development of fungal vaccines and immunotherapies to protect at-risk individuals.ThisworkwassupportedbytheNorthernPortugal Regional Operational Programme (NORTE 2020), under the Portugal 2020 Partnership Agreement, through the European Regional Development Fund (FEDER) (NORTE-01-0145-FEDER-000013), and the Fundação para a Ciência e Tecnologia (FCT) (contracts IF/00735/ 2014 to A.C., and SFRH/BPD/96176/2013 to C.C).info:eu-repo/semantics/publishedVersio

The protective effect of chondroitin sulfate on induced arthritis in rats

The protective effect of chondroitin sulfate on induced arthritis in rat

Chondroitin Sulfate Effect On Induced Arthritis In Rats

OBJECTIVE: Rodent models of osteoarthritis and rheumatoid arthritis are useful tools to study these disease processes. Adjuvant arthritis (AAR) is a model of polyarthritis widely used for preclinical testing of antiarthritis substances. We report the effect of two different doses of highly purified chondroitin sulfate (CS) pharmaceutical grade in the AAR animal model after oral administration.DESIGN: AAR was induced by a single intradermal injection of heat-inactivated Mycobacterium butyricum in incomplete Freund's adjuvant. The experiments included healthy animals, untreated arthritic animals, arthritic animals having been administered 300 or 900 mg/kg of CS daily, 14 days before AAR induction until the end of the experiment (day 28), arthritic animals having been administered 300 or 900 mg/kg of CS daily, from day 1 until the end of the experiment.RESULTS: CS was capable of significantly reducing the severity of arthritis along with oxidative stress, a consequence of chronic inflammatory processes occurring in AAR. The CS pre-treatment regimen was effective throughout the whole subacute phase, while treatment from day 1 proved effective only in the chronic period. The effects were confirmed by improved total antioxidant status and γ-glutamyltransferase activity. CS administered under a pre-treatment regimen was also able to reduce the production of pro-inflammatory cytokines, C-reactive protein in plasma, phagocytic activity and the intracellular oxidative burst of neutrophils.CONCLUSIONS: CS proved to be effective in slowing down AAR development and in reducing disease markers, thus supporting its beneficial activity as a drug in humans

Effect of nonanimal high- and low-molecular-mass chondroitin sulfates produced by a biotechnological process in an animal model of polyarthritis

BACKGROUND/AIMS: We planned to report on the effect of two nonanimal chondroitin sulfates (CSs) with different molecular masses produced using an innovative biotechnological process in an adjuvant arthritis animal model. METHODS: The experiments included healthy animals, untreated arthritic animals and arthritic animals having been administered 900 mg/kg of either of the two CS samples daily. Arthritic score, γ-glutamyltransferase (GGT) activity in hind paw joint tissue homogenates, plasmatic C-reactive protein (CRP) and pro-inflammatory cytokines IL-1β and IL-6 were assayed. RESULTS AND CONCLUSIONS: Low-molecular-mass (LMM) CS significantly reduced the arthritic score by up to about 30% from 14 to 28 days. In contrast, no significant differences were observed for high-molecular-mass (HMM) CS, even if a trend in its capacity to decrease the arthritic score by up to about 11% was observed. Additionally, LMM CS was able to significantly decrease GGT activity by approximately 31% and plasmatic CRP levels by about 9%. Both nonanimal CS samples were effective in reducing plasmatic levels of proinflammatory cytokines. A greater efficacy was also observed for LMM CS compared with a pharmaceutical-grade CS of extractive origin, while the efficacy of the HMM CS sample was found to be rather similar. The greater effect of LMM CS in reducing arthritic parameters may be related to its lower molecular mass with respect to HMM CS and natural CS

The role of redox imbalance in relation to immunological process in adjuvant arthritis

The model of adjuvant arthritis (AA) is well characterized concerning the immunological processes involved. However knowledge on the participation of redox imbalance in the progression of AA is scarce. The link between oxidative stress (OS) and immunological status in arthritis should be more precisely investigated. In our experiments, we focused on AA development in the time domain. AA was induced in rats by a single intradermal injection of Mycobacterium butyricum in incomplete Freund’s adjuvant. All experiments included healthy animals (HC) and arthritic animals not treated. We confirmed that the clinical parameters hind paw volume and body weight became significantly modified starting around day 14 after AA induction and this change was maintained until the end of the experiment (day 28). We obtained a good agreement of clinical parameters with parameters of OS. Measurements of plasmatic protein carbonyls revealed damage of proteins caused by OS. Progression of lipid peroxidation in AA was described by analysis of TBARS, HNE- /MDA-protein adducts and F2 isoprostane levels in plasma. Total antioxidant status analyzed in plasma was decreased significantly in both the acute (day 21) and the subchronic phase (day 28) of AA. Further we focused on evaluating CoQ9 plasmatic levels. The arthritic process increased significantly the level of CoQ9 in comparison to HC. Evidently, the arthritic process stimulates the synthesis of CoQ9 and its transport to plasma. In the model of AA, we observed already on experimental day 7 that AA was accompanied by an increased number of neutrophils in blood and by a more pronounced spontaneous as well as phorbol myristate acetate stimulated chemiluminescence. As the changes in neutrophils occur before the clinical parameter HPV starts to be increased, for further evaluation of neutrophil functionality we chose experimental day 7. The functionality of peripheral blood neutrophils in AA was described by phagocytosis, oxidative burst and metabolic activity. Both phagocytosis and oxidative burst were increased due to arthritis, and that despite the decreased metabolic activity. Analysis of OS in tissue showed changed GGT activity in spleen and joint homogenate accompanied by increased chemiluminescence. The OS parameters were in close relationship with time profiles of selected cytokines, chemokine MCP-1 and of C-reactive protein levels in plasma. Measurements of the immunoregulatory index in peripheral blood and lipoxygenase tissue activity (lung, liver) were also included. Our observations have evidenced the importance of pharmacological regulation of redox imbalance in arthritis. (VEGA 2/0090/08, COST B35, APVV-51-017905, APVV-21-055205